Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

AMLX

Amylyx Pharmaceuticals (AMLX)

Amylyx Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:AMLX
FechaHoraFuenteTítuloSímboloCompañía
05/03/202515:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
04/03/202515:06Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AMLXAmylyx Pharmaceuticals Inc
04/03/202506:30Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:AMLXAmylyx Pharmaceuticals Inc
04/03/202505:24Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AMLXAmylyx Pharmaceuticals Inc
04/03/202505:14Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNASDAQ:AMLXAmylyx Pharmaceuticals Inc
04/03/202505:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMLXAmylyx Pharmaceuticals Inc
25/02/202508:00Business WireAmylyx Pharmaceuticals to Participate in Upcoming March Investor ConferencesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
24/02/202508:00Business WireAmylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025NASDAQ:AMLXAmylyx Pharmaceuticals Inc
14/02/202515:30Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AMLXAmylyx Pharmaceuticals Inc
10/02/202508:00Business WireAmylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceNASDAQ:AMLXAmylyx Pharmaceuticals Inc
21/01/202508:00Business WireAmylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral SclerosisNASDAQ:AMLXAmylyx Pharmaceuticals Inc
10/01/202516:13Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AMLXAmylyx Pharmaceuticals Inc
10/01/202507:26Business WireAmylyx Pharmaceuticals Announces Pricing of Public Offering of Common StockNASDAQ:AMLXAmylyx Pharmaceuticals Inc
09/01/202518:30Business WireAmylyx Pharmaceuticals Announces Proposed Public Offering of Common StockNASDAQ:AMLXAmylyx Pharmaceuticals Inc
06/01/202508:00Business WireAmylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial OfficerNASDAQ:AMLXAmylyx Pharmaceuticals Inc
04/12/202406:30Business WireAmylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric HypoglycemiaNASDAQ:AMLXAmylyx Pharmaceuticals Inc
27/11/202408:00Business WireAmylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx ConferenceNASDAQ:AMLXAmylyx Pharmaceuticals Inc
07/11/202407:22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AMLXAmylyx Pharmaceuticals Inc
07/11/202406:00Business WireAmylyx Pharmaceuticals Reports Third Quarter 2024 Financial ResultsNASDAQ:AMLXAmylyx Pharmaceuticals Inc
04/11/202408:00Business WireAmylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024NASDAQ:AMLXAmylyx Pharmaceuticals Inc
17/10/202408:00Business WireAmylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram SyndromeNASDAQ:AMLXAmylyx Pharmaceuticals Inc
15/10/202408:00Business WireAmylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024NASDAQ:AMLXAmylyx Pharmaceuticals Inc
03/10/202414:06PR Newswire (US)Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law FirmNASDAQ:AMLXAmylyx Pharmaceuticals Inc
28/08/202407:30Business WireAmylyx Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
26/08/202417:49Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:AMLXAmylyx Pharmaceuticals Inc
12/08/202408:00Business WireAmylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and NeurodegenerationNASDAQ:AMLXAmylyx Pharmaceuticals Inc
08/08/202406:00Business WireAmylyx Pharmaceuticals Reports Second Quarter 2024 Financial ResultsNASDAQ:AMLXAmylyx Pharmaceuticals Inc
05/08/202408:00Business WireAmylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024NASDAQ:AMLXAmylyx Pharmaceuticals Inc
02/08/202408:00Business WireAmylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram SyndromeNASDAQ:AMLXAmylyx Pharmaceuticals Inc
10/07/202406:00Business WireAmylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy DesignationNASDAQ:AMLXAmylyx Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:AMLX